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Professor Michael Wellesley Whitehouse, BA, MSc, D Phil, F.R.I.C., K StJ 
Kim Drummond Rainsford, 
Emeritus Professor of Biomedical Sciences, 
Biomedical Research Centre, 
Sheffield Hallam University 
Sheffield, UK, S1 1WB 
 
This Special Editorial Section of the Journal is dedicated to the lifetime contributions 
by an outstanding multidisciplinary scientist, academic scholar, colleague, and friend 
to many throughout the world.  To describe Michael's field of specialization in a 
single term, would be a gross understatement of his training, skills and scholarship. 
Throughout about 80 years of academic life, Michael has accrued a great thirst for 
knowledge whether scientific, scholastic or cultural. He is anything but selective or 
exclusive in his approach to acquiring knowledge or focus as an academic. I have 
had the great pleasure of knowing Michael both as a research and scholastic 
colleague as well as being close friend for the best part of half a century! From the 
beginning of our working relationship, I have found that Michael has that special kind 
of quality in a natural ‘meeting of the minds’. Many occasions when we have worked 
together on research projects or writing manuscripts, I have thought that we sense 
the others’ intuition and thoughts. This is a very special quality for which I am 
immensely grateful. It is not to say we have been uncritical of one another’s ideas, 
but we have a special way of inter-weaving our ideas and working together for what 
many would say is ’for the common good’. I find that many of Michael’s colleagues 
from different disciplines, lives and backgrounds also have great respect for him, his 
ideas and thoughts. Basically, Michael gets on very well with all and manages to 
bring out the best in so many of his lifetime of contacts. Some of the contributions 
from colleagues and friends shown at the end of this article attest to these views and 
show how much he has given to many of those with whom he has had contacts 








Michael was born 90 years ago in Hendon (formerly an ancient parish of Middlesex, 
now part of Greater London) and grew up in Sheffield (South Yorkshire) and later in 
Wigan (Lancashire) where he went to Wigan Grammar School, Then, he went to 
Alsop High School in Liverpool and Highgate School (North London). The period of 
his school and later higher education at Oxford must have been very trying as this 
was during the 1930’s recession and then World War II with the bombing in and 
around the areas where he lived with his parents.  He seems to have moved around 
quite extensively during his secondary education with his father who was a leading 
secondary school English teacher.  I sometimes wonder if Michael's undoubted skills 
in writing and English expression came from his father. 
 
Certainly, he had a very high standard of education in wartime and immediate post-
war conditions, which must have been very challenging.  In 1948, he won a 
scholarship to Keble College, Oxford University where he read Chemistry and 
Biochemistry, graduating with a 1st Class honours degree with distinction in 
biochemistry.  Keble College must have been a stimulating environment, not only for 
learning the sciences, but also cultural as the first Oxford College of “the modern 
era” founded in the memory of John Keble who was a key member of the “Oxford 
Movement” that sought to recover some Catholic heritage of the Church of England.  
It was well supported in its foundation by being endowed by the Gibbs Banking 
Company who made money from a monopoly on imports of bird droppings from the 
Galapagos Islands as a source of fertiliser in Victorian times.  The college has 





While at Oxford, Michael undertook studies to be admitted as an Associate Member, 
followed later in 1962 as a Fellow, of the Royal Institute of Chemistry (London) which 
qualified him as a professional chemist. This has enabled him to analyse biological 
and medical problems through the eyes of a chemist so giving him privileged insight 
into the molecular aspects of diseases, development of therapeutic agents and as 
well as the potential properties of biological agents.  Michael can be regarded as one 
of the unique class of “biological chemists” (following the approach of the classical 
journal [J Biol Chem] and the textbook of the same title by Luberg Stryer). His post-
doctoral experience (1955-9, supported by the English Speaking Union) ranged from 
biochemistry at the University of Pennsylvania, ndUniversity of Stockholm (1960; as  
Geigy Travelling Fellow of the Empire Rheumatism Council, now the British Society 
of Rheumatology), where he had a particularly productive period working with Dr 
Harry Bostrom at the latter university. His early period involved work with the famous 
biochemist, Dr Paul Kent, as Drs Lash, Staple, Rabinowitz, Kritchevsky, Dean, 
Skidmore among others working on the chemistry, biochemistry and liver and 
mitochondrial metabolism of lipids (including those in bile), cholesterol, 
polysaccharides, sialic acids, glycoproteins, and effects of anti-inflammatory drugs 
on intermediary and polysaccharide metabolism. He undertook research while a 
Lecturer in the Biochemistry Department (headed by Prof Hans Krebs) at the 
University of Oxford (1960-1966), as well as being the Staines Medical Research 
Fellow of Exeter College, and Tutor in Physiology and Biochemistry at Keble College 
and St Peter’s Hall, Oxford. Several of his outstanding publications of the time 
appeared in Nature, leading biochemical, medicinal chemistry and pharmacological 
journals. It was this and later work on the diverse molecular aspects of drugs used to 
control inflammation and immunity to which I was particularly attracted. Michael and I 
first met and started to work together when he was a Visiting Research Fellow 
(1966-1967) and had a Commonwealth Travelling Bursary funded by the Royal 
Society) and later Senior Research Fellow (1973-1981) at the prestigious, John 
Curtin School of Medical Research (JCSMR) at the Australian National University in 
the Australian national capital of Canberra, during the 1970s when I was a 
Lecturer/Senior Lecturer in Biochemistry at the University of Tasmania Medical 
School, Hobart, Tasmania, as well as being a Visiting Fellow in the JCSMR. This 
was among the many productive periods of our collaboration which has extended 
now for over half a century. 
In between the two periods (1970-1973) in Canberra, Michael was Assistant 
Professor at the University of California at Los Angeles (UCLA) where he worked 
with the late Carl Pearson, Fran Beck (see later contribution) and others on some of 
the key immunological aspects of chronic inflammatory diseases especially the roles 
of adjuvants and lymphocytes.    
Since we first started to collaborate in 1975, we have had a very productive and 
stimulating friendship. Sometimes this was accompanied with intense discussions 
and critical encounters, but these had very positive outcomes. A few occasions this 
led to an agreement to disagree, but from my side an immense respect and deep 




our research not only on a broad range of projects focussing on exploring and 
modifying the actions of salicylates, and other NSAIDs and analgesics in attempts to 
make these drugs safer, especially to the gastro-intestinal tract, as well as to be 
more effective therapeutically. 
We tried hard over the years to encourage clinical exploitation of these key findings 
and observations. Most notable was with leading pharmaceutical companies, some 
of the principal scientists, medical directors and clinicians, as well as with 
management and laboratory staff.  Many of these associations were very useful 
insights into industrial approaches and the requirements and difficulties in meeting 
the diverse regulatory and clinical requirements for getting drugs into clinical use, as 
well as that strange entity known as the market. We did achieve some success, but it 
has to be said here were many disappointments (to put it mildly). Overall, our 
experiences in working with the pharma industry could be summarized (in hindsight) 
as being profoundly negative even though in many cases we had very strong support 
from rank and file, researchers and clinicians. Often, we hit a log-jam mostly middle-
order managers and marketers with deeply entrenches views, many of which were 
based on arcane concepts and ideas. A key point was, however, that in many cases 
our discoveries and developments were made on their own company products, 
especially on aspirin and other salicylates. we and our own scientific advisors and 
colleagues genuinely believed these would benefit both, the company and us. With 
one or two exceptions these proved not to be the case as senior management (often 
who had little understanding of the clinical benefits or knowledge of the fields in 
which the discoveries were made or their benefits to patients) often actively blocked 
or connived to derail exploitation and development of the innovative forms of the 
drugs either because (a) it would be a counter-development to the company’s 
existing products or product range, (b) the risk commercially could not be redirected 
from disadvantages to advantages, most managers in the pharmacy industry are 
inherently risk-averse and have one eye on the shareholders (who in most cases are 
non-scientists, non-physicians and don’t even have the vaguest understanding of the 
drugs in development) or  the complexity of the deep-seated politics in big pharma, 
or (c) the attitudes, poor scientific quality and background as well as attitudes, 
intrinsic risk-adverse negativity of national and multinational (especially in the 
European Union and its member states) of the regulatory agencies that govern 
approval of new products. While very occasionally encounters or interactions with a 
few members of these agencies have been positive, they are governed by negative 
pressures from political and bureaucratic masters. Thus, the whole process of  taking 
a promising (often very promising) new discovery or development through company 
and drug-regulatory processes is rather like seeing hoses jumping over and falling at 
a grand national steeplechase (especially like that of the annual event in Aintree, UK. 
We did go through many exhaustive processes including getting university 
committee or administrative approvals, patent applications,  many of which were very 
challenging and intellectually unique exercises in themselves (writing a patent 
specification is in my view a somewhat arcane art–science form, wrapped in its own 
legalese, but which can be very rewarding, especially when the patent is finally 




the Patent Office or agency concerned. Working with patents attorneys can be both 
an intellectually challenging and a satisfactory experience that proves you have to 
know your invention, competitive other discoveries and developments. 
Finally, there is the ever-expanding involvement of university administrators and 
deans. In a number of cases we had some encouragement and support from these 
senior officers. However, a few of the middle order management seem to see us a 
‘cash cows’ with rapacious appetites for money and royalties to be siphoned off into 
their coffers and without recognition of the hard work done by those who have been 
the creators, fund-raisers and who have done everything to create novel drugs. As 
Michael and I know only too well, the foot soldiers never receive any gratitude – 
maybe the odd award and promotion but not without dripping envy and jealousy. We 
have the T-shirts but they are all blank. 
The next entrepreneurial venture which Michael and I have been involved in over the 
years is the communication of our science as well as ideas and criticisms, and that of 
our highly valued colleagues. This has taken the form of the development of a 
journal devoted to the broad subject area which up to the late 1980’s had been 
somewhat neglected or left to other journals with less specialized expertise, focus or 
scope. Enter 'Inflammopharmacology', a journal dedicated to the pharmacology of 
inflammatory diseases and their associated aches and pains, their clinical treatment 
and pharmacotherapy. The history of the development and achievements of this 
journal since its inception in 1991 has been told elsewhere (Rainsford, 2016). Since 
its inception, the journal has benefited over the years from many ideas, 
commentaries, publications and concepts initiated and developed by Michael. 
Among the many significant concepts begun by Michael was that of 'Conditional 
Pharmacology' which he pioneered (Whitehouse, 1987, 1991) and developed with 
the late Professor Barrie Vernon-Roberts (University of Adelaide, Australia) 
(Whitehouse and Vernon Roberts, 1991) and Dr. Michael Powanda (M/C Biomedical 
Consultants LLC, Mill Valley, CA, USA) (Powanda, 1995). 
In essence, this concept states that (a) inflammatory processes may alter the basis 
for the actions of drugs that have been designed to act on these processes by 
means of altering the receptors, enzyme activities , drug metabolism or other physio-
pathological mechanisms that are affected by these agents, and (b) that through 
these actions, the alteration of these inflammatory processes they may in turn affect 
those mechanisms (e.g. drug metabolic enzymes) that influence their mode of 
action. 
This elegant, if little appreciated, concept may be summarized as the vicious cycle of 
drug actions and influences of their consequences; elements of this vicious cycle 
may have positive therapeutic consequences and possibly negative or positive 
toxicological impact. 
Another part of our collaboration has been in the contribution to the ethos and 
development of the International Conference series which initially began (in 
collaboration with the late Professor Giampaolo Velo, Verona, Italy) as the “Side 
Effects of Anti-inflammatory/Analgesic Drugs” conferences and then progressed to 




Side Effects of Anti-inflammatory Drugs” and also Safety and Efficacy of Non-
Prescription (OTC) Analgesics and NSAIDs which was held in collaboration with Dr. 
Michael Powanda. These were followed with the conference series on 
“Inflammopharmacology”, held in collaboration with Dr. Brian Callingham (University 
of Cambridge and Queens’ College, Cambridge) (Rainsford, 2016). Not only did 
Michael make presentations of major significance to these conferences, but also 
challenged many of the arguments and data that were presented and contributed to 
the ideas and planning of these conferences.  
It is interesting to reflect back to the earliest conference that we organized in 1975 
which was held on “Aspirin and Related Drugs. Their Actions and Uses”. (Rainsford 
et al, 1977). Here we presented concepts of how aspirin and related drugs produced 
their anti-inflammatory actions as well as causing side-effects. Notably, presented 
data on salicylates that were derived from natural products and how these might 
produce anti-inflammatory effects and have differing actions (or inactions) on platelet 
aggregation. Strikingly, these observations are relevant today and may still be worth 
consideration in the pharmacotherapy of inflammatory conditions. 
From these early observations on salicylates derived from natural products, Michael 
and his colleagues have continued to have interests in natural products as anti-
inflammatory and analgesic activities. Among the most notable of these has been the 
ethanolic extract of the celery seed derived from Amritsar (India) which has proven 
clinical activity as well as gastro-intestinal protection (Rainsford et al, 2015). The 
latter extends to an important and unique action found in a phthalate component of 
celery seed oil which has since been found to have anti-helicobacter activity (Zhou et 
al, 2009).Our interests and research work in this and many other natural products, as 
well as development of derivatives thereof would not have been possible without the 
initial and continued interest by Michael. 
Like so many research collaborations, the unique and highly significant results come 
from a meeting of minds, personal relationships and long-standing friendship. We 
owe an immense debt of gratitude to Michael for all these especial qualities. 
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Mini Symposium ‘Commemorating Life and Works of Leading 
Australian Scientists in the Fields of Inflammation and 
Pharmacotherapy of Inflammatory Diseases’ 
Garry G Graham 
Department of Pharmacology and Toxicology 
St Vincent’s Hospital, University of New South Wales, 
Darlinghurst, NSW, Australia 
 
The reviews are based on a small symposium held in Adelaide on July 5, 2019. The 
symposium was organized by Professor Kim Rainsford, Sheffield Hallam University, 
Sheffield and University of Adelaide and Professor David Haynes, University of 
Adelaide. 
An important aim of the symposium was to commemorate the work of Professor 
Michael Whitehouse who has freely given his time and valuable research advice to 
all presenters at the symposium. As outlined below, Professor Whitehouse has 
published over a wide range of research areas. Not surprisingly, he has a 
considerable publication record. Reference to Google Scholar indicates that he has 
published 422 papers with 9324 citations. His h-index, a measure of interest in his 
publications is 53.  
Studying Chemistry and Biochemistry at Oxford started Professor Whitehouse off on 
a line of research that led through various aspects of molecular medicine; including 
chemistry of animal polysaccharides, sterol metabolism and ischemic heart disease, 
cartilage degradation and osteoarthritis, toxicity of adrenocorticoid hormones, non-
steroidal anti-inflammatory drugs and natural products. Professor Whitehouse has 
conducted many studies on the evaluation of the anti-inflammatory activity of 
compounds in experimental animals and is an expert on the details of these often-
difficult studies. In research management, Professor Whitehouse was very much 
involved in the establishment of committees for the ethical examination of animal-
based research. 
To Professor Whitehouse, the world is chemical in nature and cannot be understood 
without knowledge of the chemical properties of compounds under study. His initial 
studies in pathology were on mucins in the gastrointestinal tract and, because of his 
interest in the relevant chemistry, was a co-author of a book on the constituent 
amino-sugars (Kent, Whitehouse 1955). This book is still being referenced. 
Professor Whitehouse has conducted much research in Australia, starting in the 




Australian National University, Canberra, with the initial assistance of Professor Sir 
Howard Florey in 1966 – 1967 and again 1973 – 1981. In the intervening period 
(1968 – 73), Professor Whitehouse was Professor of Medicine and Acting Professor 
of Pharmacology at University of California, Los Angeles (UCLA). From 1981 to 
1994, Professor Whitehouse was a senior researcher successively at three South 
Australian institutions, Flinders University of South Australia, the Department of 
Pathology and Institute of Medical & Veterinary Science, University of Adelaide, and 
the University of South Australia. He has also worked for several years with 
Professor Michael Roberts, School of Pharmacy, University of Queensland. 
Currently, he is an Honorary Research Professor in Experimental Medicine at Griffith 
University in Queensland.  
While at UCLA, Professor Whitehouse was a consultant to Riker Laboratories with a 
particular interest in the anti-inflammatory drugs used in the treatment of rheumatoid 
arthritis. At the time, Riker Laboratories were developing an unusual anti-rheumatic 
drug and because of his expertise in chemistry, Professor Whitehouse rapidly and 
correctly identified the drug as reacting with sulfydryl (thiol) groups.  
Professor Whitehouse has published many papers on the anti-inflammatory and anti-
cancer activity of metals, including complexes of zinc, copper, silver, platinum, and 
gold. He has also shown that colloidal gold has anti-inflammatory activity. This work 
was published from the 1970’s onwards but is still being referenced, an indication of 
the novelty and value of Professor Whitehouse’s research approach. Professor 
Whitehouse’s two papers on colloidal gold are of note. Metallic gold is generally 
considered to be inert. However, Professor Whitehouse showed that colloidal gold is 
not inert but has anti-inflammatory activity (Brown et al.  2007; 2008). 
Consistent with these findings, gold pellets also have anti-inflammatory activity and 
have continued use and investigational studies as local injections for anti-
inflammatory action in hip dysplasia in dogs (Jaeger et al. 2016). This activity is due 
to dissolution of gold from the surface of the pellets which may be increased with 
greater pharmacological effect due to the greater surface/mass ratio of colloidal gold 
than gold pellets.   
Other notable and widely cited work of Professor Whitehouse includes his finding 
that thiocyanate, SCN-, a normal body constituent, has pro-inflammatory activity in 
rats (Whitehouse, Jones 2009) but, on the other hand, may decrease neutrophil-
induced tissue damage (van Dahlen et al. 1997). Professor Whitehouse was 
responsible for the introduction of the term, 'Conditional Pharmacology' which is 
defined as the modification of the pharmacological actions of a drug changing 
pathophysiological conditions or the addition of a compound which is not a drug. 
Professor Whitehouse et al (2013) first discussed this concept on how thiocyanate 
modifies the activity of silver and the anti-rheumatic gold complexes. Further work on 
conditional pharmacology, particularly with thiocyanate, is warranted from the work 
of Professor Whitehouse. 
Another example of early work of Professor Whitehouse was his work on emu oil 
which has been widely applied to the skin by Australian aboriginals. The anti-




(1998) Unfortunately, Professor Whitehouse could not continue this work due to 
patenting questions and consequent lack of support by funding organisations. 
However, his work has been confirmed by several other groups and is a further 
example of research studies initiated by the work of Professor Whitehouse. 
Professor Whitehouse is now 90 but is still an active researcher putting forward 
novel ideas in pharmacology and toxicology, particularly with his wife, Desley. 
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The Evolution of Conditional Pharmacology 
M.C. POWANDA 
M/P Biomedical Consultants LLC, 435 Marin Avenue, Mill Valley, CA 94941, USA 
The concept of conditional pharmacology and toxicology originates in the studies of 
drug-disease interactions in inflammation done by Dr Whitehouse and his colleagues 
(Whitehouse, 1985, 1991; Whitehouse and Vernon-Roberts, 1991). The concept 
originally focused on how expression of anti-inflammatory activity may require pre-
existent inflammatory mediators/hormones. A few years later I commented on how 
broad the implications of conditional pharmacology might be, even extending the 
concept to preclinical toxicology studies (Powanda 1995). 
As I stated then and now recapitulate, “Conditional pharmacology/toxicology involves 
employing the physiological or metabolic activity, the genetic and/or molecular 
structure of the host, of the disease process and/or of the parasite to activate and 
target the drug or biologic, as well as to regulate and delimit its activity. This 
definition emphasizes the multifactorial aspects of the approach and sets the stage 
for a listing of some existing as well as proposed examples of use of the concept in 
the treatment of inflammatory diseases and in the treatment of neoplastic and 
infectious diseases. This concept is also an underlying assumption, and expected 
consequence, of successful gene therapy.” 
Almost three decades later, there are a number of drugs and biologics whose actions 
depend on the presence of a receptor or an overactive gene. In breast cancer, a 
gene called HER2 makes too many copies of itself in about 20% of people with 
breast cancer. Trastuzumab (Herceptin), an antibody, is the standard treatment for 
this type of breast cancer apparently acting by sticking to certain areas on cancer 
cells, stopping them from growing, as well as signalling the body's immune system to 
attack cancer cells (Romão, et al, 2017). 
About 2 out of 3 breast cancers are hormone receptor-positive. Their cells have 
receptors (proteins) for the hormones estrogen (ER-positive cancers) and/or 
progesterone (PR-positive cancers) which help the cancer cells grow and spread. 
Tamoxifen blocks estrogen receptors on breast cancer cells. It stops estrogen from 
connecting to the cancer cells and telling them to grow and divide. While tamoxifen 
acts like an anti-estrogen in breast cells, it acts like an estrogen in other tissues, like 
the uterus and the bones. Because of this, it is called a selective estrogen receptor 
modulator (SERM). It can be used to treat women with breast cancer who have or 
have not gone through menopause (Kahlenberg & Fox, 2011). 
In the case of rheumatoid arthritis, there are a series of biologics that work by 
interfering with the activity of tumor necrosis factor. This is a key immune system 
cytokine. These drugs include:  adalimumab, etanercept, infliximab and golimumab. 
Another cytokine target is interleukin-1 (IL-1); Anakinra blocks the action interleukin-
1. Tocilizumab is a biologic that works by blocking the cytokine interleukin 6 (IL-6). In 
contrast, Abatacept is a selective T-cell co-stimulation modulator, while Rituximab, a 
CD20-directed cytolytic antibody, appears to help control RA by destroying another 




In November 2012, the U.S. Food and Drug Administration (FDA) approved 
tofacitinib citrate, a drug "to treat adults with moderately to severely active 
rheumatoid arthritis who have had an inadequate response to, or who are intolerant 
of, methotrexate.” Tofacitinib is a Janus-associated kinase (JAK) inhibitor. It works 
by blocking a cellular signalling pathway inside cells. It can be taken orally. 
The above drugs/biologics all depend on some factor/factors related to the disease 
being present in the extra or intracellular milieu, as ‘conditional pharmacology’ would 
predict. Despite this array of drugs and biologics for breast cancer and rheumatoid 
arthritis, it is clear that these agents may be ineffective or less effective in some 
cases (5-7). Also, none of these is a cure. Plus, virtually all these agents display 
toxicities (8). It remains to be seen whether other disease related factors can be 
identified and targeted so as to increase efficacy and decrease toxicity of cancer and 
arthritis treatments.  
In the case of drugs, safety and efficacy may be related to drug–drug interactions, 
either metabolism mediated drug interactions or transporter mediated drug 
interactions. In concert with metabolizing enzymes, transporters can govern a drug’s 
disposition and pharmacological action. The US Food and Drug Administration has 
recently published a final guidance document to assist investigators in determining 
whether drugs are affected by metabolism and or transporter interactions (9). 
The continuing hope inherent in the concept of ‘conditional pharmacology’ is that the 
discovery of new, even more highly specific disease related targets may help in the 
development of drugs and biologics that are both more efficacious and, if possible, 
less toxic. 
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A personal appreciation of Professor Michael W. Whitehouse 
 
Frances J W Beck 
Dept. of Medicine, School of Medicine, Wayne State University 
Detroit, Michigan, USA 
 
 
Early in the decade of 1970 at the University of California, Los Angeles (UCLA), one 
found Professor Michael W.  Whitehouse investigating mediators of inflammation 
and their pathological importance in rheumatoid arthritis at a time when the new field 
of Immunology was at its rudimentary beginning. In addition, he was a research 
consultant to the late Dr. Louis Levy at Riker Laboratories (now 3M) in Northridge, 
California where questions concerning effectiveness of anti-inflammatory compounds 
were also being addressed.  At Riker, where compounds were both manufactured 
and evaluated, the question asked was: “Are these compounds effective in reducing 
the inflammatory response?”. However, most testing was done using healthy 
animals.  Several years later, I was honoured to join Professor Whitehouse at UCLA 
where the question was turned around:  “ Does the physiological state  
(healthy/unhealthy {disease}) of the subject  alter the ultimate efficacy of the drug 
being administered”.  At the time, it was an interesting exercise in experimental 
research, but eventually, over time, it became clear that the answer would be a 
resounding “YES!”  and is the central theme of today’s concept of 'Conditional 
Pharmacology' applied in nutrition, drug development, ageing studies and particularly 
in cancer research as well as in other disciplines.  Thus, Professor Whitehouse had 
at that time laid the groundwork for both of our individual careers in academic 
research even though our respective careers would soon diverge.  Two years later, 
Professor Whitehouse relocated to Australia where he would continue to investigate 
this subject in search of better treatments for arthritis for the rest of his academic 
career. However, before leaving, he was instrumental in providing arrangements with 
the late Dr. Carl Pearson that would allow me to continue our research at UCLA for 
the interim between his exit and the appointment of a new investigator to his former 
position.  This provided for me an unprecedented opportunity to be an independent 
investigator responsible for the design and execution of experiments leading to 
several publication years before I was able to obtain advanced degrees. It was the 





In Australia, Professor Whitehouse continues to define the mechanisms by which 
adverse physiological conditions would affect drug efficacy using unique animal 
models that were developed during his time at UCLA. For his extensive research into 
the treatment of arthritis and inflammation, he was elected to Life Membership in the 
Australasian Society of Clinical and Experimental Pharmacologist and Toxicologists.  
Although unaware of each other’s work, Professor Whitehouse’s research into the 
effect of zinc on the inflammatory response in a compromised system paralleled our 
similar studies at Wayne State University School of Medicine, Detroit, Michigan 
under the direction of Dr. Ananda Prasad. There, we demonstrated that multiple 
molecular mechanisms involved in the production and expression of inflammatory 
cytokines as well as the regulation of target receptors were altered in the 
physiological  zinc deficient state whether zinc deficiency was nutritionally, 
experimentally or disease induced or genetically inherited.  Later, in collaboration 
with the University of Queensland, Professor Whitehouse founded and managed 
research at Pharma Quest, a Consultancy to promote research on natural 
medicines. Near the same time, my work at the Barbara Ann Karmanos Cancer 
Institute in Detroit, Michigan with Drs. Ramzi Mohammad and Ayad Al-Katib, was 
centered in evaluating the efficacy of anti-cancer compounds also isolated from 
natural sources. That cancer cells respond to specific drugs quite differently from 
that of normal cells is possibly the most complex form of the 'Conditional 
Pharmacology' concept embraced at UCLA forty-five years earlier and now requires 
investigative research be executed at the molecular level. The search for compounds 
that modulate specific intracellular molecules aberrantly expressed in cancer cells 
but not in normal cells is at the core of cancer research pharmacology. 
Before Professor Whitehouse became semi-retired from active research, our paths 
would cross once again. It was a privilege to share results of our respective research 
careers with each other and with his colleagues at the University of Queensland in 
2002. Conversations concerning all manner of things discussed within the 
“Whitehouse Research Family” at UCLA years ago were easily continued as if it 
were but yesterday. Old acquaintances were remembered (Drs.  Peter Fowler,  J. P. 
Famaey,  John Carson, Kim Rainsford to name a few) and new ones established.  
Sprinkled between seminars, conferences, presentations and experiments were 
short trips to explore nearby surrounding Australia with his dear wife and colleague, 
Desley Butters.  Recently, he was awarded Chevalier of the Hospitalier of St. John’s 
of Jerusalem, one of many accolades he has received throughout his lifetime. On 
behalf of the many, many individuals who have benefited from Professor 
Whitehouse’s support and friendship we say “Congratulations on your many 
contributions to science, medicine and humanity, the honours are well deserved.”  To 
Professor Whitehouse, the true honour for each of us, however, is to have been and 








Some Biographical Reflections 
Prof. M. W. Whitehouse 
Griffith University, School of Medicine (Gold Coast Campus), and School of 
Biomedical Sciences (Nathan Campus), 
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Michael was born in Middlesex, North London, in 1930, both his parents being 
schoolteachers.  He was raised first in Sheffield (Yorkshire), Wigan (Lancashire) and 
finally in Liverpool (Merseyside) from where he was twice evacuated to Wales, 
before heading south, first to Highgate School (North London) and then Oxford 
University. 
After studying Chemistry and Biochemistry at Oxford he went off on a line of 
research that led through various aspects of molecular medicine; including chemistry 
of animal polysaccharides, sterol metabolism and ischaemic heart disease, cartilage 
degradation and osteoarthritis, toxicity of the adrenocorticoid hormones and non-
steroidal anti-inflammatory drugs, including complexes of the coinage ‘noble metals’ 
Cu, Ag & Au used as ‘novel’ drugs to control inflammation.  Resulting from a long-
standing interest in immunological adjuvants as aetiologic agents in (poly)-arthritis, 
he undertook a search for environmental arthritogens (oils, bacteria) and for natural 
anti-inflammatories.  These included those sourced from Aboriginal (Australia), Maori 
(New Zealand), Melanesian and Ayurvedic (India) traditions of healing. Recently he 
has returned to nutritional medicine, believing that low cost 'Preventative Medicine' is 
the most needed item for helping people world-wide to increase their wellbeing – 
without recourse to the expensive and/or labile (i.e. those needing refrigeration) 
medications promoted by the Western pharmaceutical industry. 
For personal support he successively taught organic chemistry, biochemistry, 
endocrinology, molecular pharmacology, immunology, molecular pathology and 
toxicology in six medical schools (Oxford, Pennsylvania, Ohio State, California Los 
Angeles, Adelaide, Flinders South Australia), and worked in six hospitals (Serafima, 
Stockholm, University of California at Los Angeles, Royal North Shore, Sydney, 
Royal Newcastle, NSW, Christchurch, NZ, and Princess Alexandra, Brisbane).  He 
reckons his best teaching (and stimulating learning) experiences were located 
outside the norm: particularly In the South Australian College of Natural Therapies 
(Adelaide, Australia) and the Canberra College of Advanced Education – all with 
eager mature students but regrettably little in the way of relevant textbooks. 
One of the highlights of his early career was having the Australian pathologist 
Howard Florey OM, Nobel Laureate, President of the Royal Society UK and 
Professor of Pathology at Oxford as his ‘technical assistant’ (!) while doing research 
for the D.Phil degree at Oxford.  This happened because Florey was rather fearful 
that cortisone, the new wonder drug for arthritis and septic shock, would damage the 
production of protective gastrointestinal mucins, just as it could severely damage the 
production of other carbohydrate polymers present in cartilage, skin, the vasculature, 




Research Council would only provide small quantities to qualified investigators who 
would personally administer the drug, either to patients or for animal studies.  So 
Florey began the experimental work by injecting duodenal-cannulated rabbits and 
Michael then measured intestinal mucin production (using the incorporation of 35S-
sulphate as a new tool to monitor mucin biodynamics).  Outcomes from this early 
experience were learning to use radiotracers for metabolic studies and that 
toxicology was a most important aspect of therapeutics.  Furthermore, personal 
status should be no hindrance to scientific collaboration.  Subsequently, when the 
opportunity came to take sabbatical leave from Oxford (1966) to be a Visiting Fellow 
at the Australian National University, Canberra, Florey kindly facilitated this visit. 
Another instructive experience was learning that if you saw a need for, or discovered 
a new research tool, you were then either ignored for an unwarranted period or 
almost immediately overwhelmed by other editors and authors who felt challenged to 
out-publish you.  When Paul Kent and Michael wrote a book on the amino sugars in 
1954, the first since PA Levine’s Monograph on muco-substances written in 1926, 
very soon thereafter a four volume compendium on glycosaminoglycan was 
produced by E. Balasz for Academic Press.  Subsequently Bob Scherrer (then at the 
3M Research Minneapolis) and Michael prepared and edited a two volume treatise 
on Anti-Inflammatory Agents in 1974 (Academic Press NY).  This was a monumental 
effort bringing together an immense literature on the medicinal chemistry of non-
steroidal and steroidal anti-inflammatory drugs.  This book is remarkable in that its 
contents are still current today.  In 1967, Peter Ghosh and Michael serendipitously 
discovered the fluorigenic reagent, NBD Chloride for detecting and labelling amino 
acids and peptides.  It is still in use today, having been exploited and cited in over 
2000 publications. Later, a look-alike NBD fluoride was patented, duly promoted and 
became undoubtedly profitable. 
Another highlight was collecting and collating the supportive data for seven labour-
intensive publications that gave him particular satisfaction.  These were: 
1964.  Uncoupling of oxidative phosphorylation by salicylate analogues: relationship 
of structure to activity.  Biochem Pharmacol 13:319-336 
1969.  Passive transfer of adjuvant-induced arthritis and allergic encephalomyelitis in 
rats using thoracic duct lymphocytes.  Nature 224:1322 
1974.  Freund’s Adjuvant: relationship of arthritogenicity and adjuvanticity in rats to 
vehicle composition.  Immunology 27:311-330 
1982.  Rat polyarthritis: induction with adjuvants composed of various mycobacteria 
(and oils) from the environment.  J Rheumatol 9:494-501 
2009.  Pro-inflammatory activity in rats of thiocyanate, a metabolite of the 
hydrocyanic acid inhaled from tobacco smoke.  Inflamm Res 58:696-704 
2010.  Questioning the safe use of vaccines containing squalene.  Immunol & Cell 
Biol 88:497-499 





The passage of time is still affording judgement and (re)appraisal of these 
publications. 
Michael particularly appreciated being awarded research scholarships/fellowships 
throughout his career, particularly from the Medical Research Council UK, the 
English-Speaking Union, the Royal Society UK, Empire Rheumatism Council (now 
Arthritis UK) London, Exeter College Oxford, the Australian National University 
(ANU) Canberra, the National Academy of Sciences and National Institute of Health, 
Washington DC and the 3D Centre, University of Queensland.  Currently he is 
Honorary Professor of Experimental Medicine at Griffith University, Gold Coast, 
Queensland, Australia, still particularly interested in alternative/neglected anti-
inflammatories. 
None of this would have been possible without the moral support of various heads of 
departments, colleagues and the able assistance of many storekeepers and animal 
attendants.   
After-thoughts 
• Nowadays, free thinkers and bench workers are being stifled with demands 
for frequent reports, changes in thinking and inability to discuss ideas outside the 
immediate group, etc.  Gone are the days where a disparate group of researchers 
could sit drinking tea or having a beer together, discussing what they were doing and 
especially in sharing ideas. 
• Its almost impossible to believe that the head of a pharmaceutical company 
would give one a cheque to assist travel expense and say, “Come back in 12 months 
and tell me what you’ve found out.”  The ‘bean counters’ and ethics committees 
would be unable to relate to such a happening.  Yet, this is precisely what Lou Sarett 
of Merck USA did in 1966.  After 10 months Michael hadn’t found the golden elixir 
but had shown that methyl glyoxal (pyruvaldehyde) and cortisol aldehyde were 
potential endogenous metabolites that might behave as pseudo-NSAIDs in 
regulating lymphoid and epithelial cells.  (J Pharm Pharmacol 1967; 19:590-595) 
• In 1992 while working in Adelaide he was asked by Peter Ghosh (then in 
Sydney) to help investigate the therapeutic potential of emu oil.  Since European 
settlement in Australia, stories abound about the successful treatment of muscular 
ailments with emu oil as practised by the First Peoples of Australia.  The West 
Australian Aboriginal community at Wiluna, with enlightened support from friends in 
Perth WA commissioned this work.  So began an adventure learning about the life 
cycle and productivity of emus.  [A case of pharming for farmaceuticals?] A 
provisional patent (PP) was lodged from Western Australia to protect their intellectual 
property.  However, for some inexplicable reason the Australian Patents Office 
released the PP.  An Aboriginal community in Queensland then claimed priority for 
the intellectual property but had never demonstrated its validity.  The end result was 
that the good work and knowledge obtained was unable to be further financed. 
• He was rather surprised on returning to Australia in 1973 to find that few, if 
any, universities had established animal ethics committees.  In the UK and USA he 




veterinarians, he set down some guidelines for working with animals in Australia, 
responding to a request from the National Health and Medical Research Council 
(NH&MRC).  These guidelines, largely based on those in the UK, were written in a 
user-friendly style – unlike the very restrictive guidelines issued today. 
• Later on, he was even more surprised when the Australian Government, 
having set up a Department of Productivity and Innovation, then awarded support for 
development of non-gastrotoxic aspirin formulations in collaboration with Kim 
Rainsford; only to have it rejected by the ANU  on the grounds that they might be 
providing scarce facilities to promote a commercial enterprise!! [Good sense 
eventually prevailed:  but it was an uncomfortable experience being branded a 
pariah by the ‘pathology establishment’ and initially denied approved government 
support.] 
• Commercial collaborations within Australian university laboratories during the 
early 1970s were not generally encouraged.  Yet, within 12 months of his leaving 
ANU the medical school was actively promoting such activities.  Such a contrast to 
today when universities are encouraged to undertake research work for 
pharmaceutical and other organisation with shared patent rights and a business 
office to supervise negotiations. 
• While at UCLA the then Californian governor (R Reagan) ordered the 
university’s closure in response to a vigorous student protest about extending the 
Vietnamese war into Cambodia.  This lock-out also affected the university’s 
peripheral research and medical research on campus.  No provision had been made 
for the welfare of animals under treatment. It was enforced by the presence of armed 
police, who had no interest in conducting further dialogues. So Michael used to crawl 
through the bushes to gain entry to the laboratory by the fire escape in order to feed, 
care for and treat his animals.  This all had to be done by daylight, as anyone moving 
around at night was asking for serious trouble (police policy then being shoot first, 
ask questions later).  This injustice/melodrama was further extended to the teaching 
staff who were then denied their incremental pay-rise that year – these extra funds 
being distributed to others who were no more deserving.  In fact, the floor cleaner got 
a double bonus!  The medical school teaching staff voluntarily repeated interrupted 
courses as students reappeared, being brave enough to try to continue ‘as normal’. 
Michael taught his contribution to the pharmacology and toxicology course three 
times over and had accordingly to conduct three sets of examinations.  This 
determination to continue the education of medical students was never recognised 
by the State authorities.  In fact, for supporting student rights to object, many 
teaching staff were ‘punished’ by being denied agreed prospects of promotion or 
tenure, as the University of California’s five-year plan was then junked/torn up by the 
State legislature.  This was yet another re-enactment of the serious divide between 
politicians and educators.   Consider the fate of Socrates 399 BCE "refusing to 
recognize the gods recognized by the state" and of "corrupting the youth." 
(www.eyewitnesstohistory.com) 
• An ill-mix of politics and science had got him into trouble previously in 




Rheumatology in Prague he found his way to the home of a Dr X, a geneticist who 
had taught at the famed Charles University but who, unbeknownst to Michael, was 
apparently under house arrest.  [His crime: pointing out that T.D Lysenko (a 
Russian)’s neo-genetics, as approved by Stalin, was false and that G. Mendel (a 
Slovak)’s theory should still be taught.  For this, he was stripped of Czech 
citizenship, declared an enemy of the State, and therefore ineligible for a job and 
receipt of food rations.]  Michael’s visit was on behalf of a supporter in London who 
was trying to find Dr X a job in the UK; but meanwhile asked him to check on his 
welfare and give him $US50.  The State police apparently knew of this visit and 
subsequently followed Michael around because his visitor’s visa was peremptorily 
terminated.   The president of the Congress and Professor of Balneology in Prague, 
Franz Lenoch, spoke to Michael, insisting the conversation be in Latin; a somewhat 
arduous task for Michael not having used this classical language for 17 years.  Very 
fortunately Milan Adam, a medical physiologist, took care of him as, no longer having 
a valid visa, he had to leave the country the next day.  Milan made sure he was 
delivered to the airport where he had a body search and was stripped of all cash on 
his person, quite a memorable visit!  Michael was able to add ‘persona non grata in 
the CSSR’ to his CV!  As it so happened when he next applied for a Czech visa to 
attend a pharmacology congress, he had no trouble; the visa having been completed 
in the Czech language.   
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